Hypertension is believed to be the single greatest factor influencing the development of heart failure, particularly heart failure with preserved ejection fraction, also known as diastolic heart ...

It is a common perception that approximately 50% of heart failure (HF) patients present with a normal or near-normal left ventricular (LV) ejection fraction ("HF with preserved systolic function"), ...

"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this 12-part journey through a disease state ...

Medera is a clinical-stage biopharmaceutical company focused on targeting difficult-to-treat and currently incurable diseases by developing a range of next-generation therapeutics. Medera operates via ...

Columbus-based Ohio State University’s Richard M. Ross Heart Hospital is the first in the world to study the clinical benefits of a device used to treat diastolic heart failure. Diastolic heart ...

Of the estimated five million patients in the U.S. diagnosed with heart failure annually, nearly half will have heart failure with preserved ejection fraction (HFpEF). Also known as diastolic heart ...

M ore than 6 million adults in the United States have heart failure. Of these, about half have diastolic heart failure and the other half have systolic heart failure. In February 2021, the U.S. Food ...

Corvia Medical Inc. has closed $54 million in equity financing to support a confirmatory trial for its Interatrial Shunt Device, designed to reverse diastolic heart failure (HF), otherwise known as ...

Incidence of cardiotoxicity after high cumulative dose of anthracyclines in adult patients with advanced soft tissue sarcomas: A systematic review and meta-analysis. Arterial stiffness and aortic ...